Suppr超能文献

复发性艰难梭菌感染:从定植到治愈

Recurrent Clostridium difficile infection: From colonization to cure.

作者信息

Shields Kelsey, Araujo-Castillo Roger V, Theethira Thimmaiah G, Alonso Carolyn D, Kelly Ciaran P

机构信息

Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States.

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Lowry Medical Office Building, Suite GB 110 Francis Street, Boston, MA 02215, United States.

出版信息

Anaerobe. 2015 Aug;34:59-73. doi: 10.1016/j.anaerobe.2015.04.012. Epub 2015 Apr 27.

Abstract

Clostridium difficile infection (CDI) is increasingly prevalent, dangerous and challenging to prevent and manage. Despite intense national and international attention the incidence of primary and of recurrent CDI (PCDI and RCDI, respectively) have risen rapidly throughout the past decade. Of major concern is the increase in cases of RCDI resulting in substantial morbidity, morality and economic burden. RCDI management remains challenging as there is no uniformly effective therapy, no firm consensus on optimal treatment, and reliable data regarding RCDI-specific treatment options is scant. Novel therapeutic strategies are critically needed to rapidly, accurately, and effectively identify and treat patients with, or at-risk for, RCDI. In this review we consider the factors implicated in the epidemiology, pathogenesis and clinical presentation of RCDI, evaluate current management options for RCDI and explore novel and emerging therapies.

摘要

艰难梭菌感染(CDI)日益普遍,预防和管理具有危险性且颇具挑战性。尽管受到国内外的高度关注,但在过去十年中,原发性和复发性CDI(分别为PCDI和RCDI)的发病率仍迅速上升。主要令人担忧的是RCDI病例的增加,这导致了严重的发病率、死亡率和经济负担。RCDI的管理仍然具有挑战性,因为没有统一有效的治疗方法,对于最佳治疗方案没有坚定的共识,而且关于RCDI特异性治疗选择的可靠数据很少。迫切需要新的治疗策略来快速、准确和有效地识别和治疗患有RCDI或有RCDI风险的患者。在本综述中,我们考虑了与RCDI的流行病学、发病机制和临床表现相关的因素,评估了RCDI的当前管理选择,并探索了新出现的疗法。

相似文献

1
Recurrent Clostridium difficile infection: From colonization to cure.复发性艰难梭菌感染:从定植到治愈
Anaerobe. 2015 Aug;34:59-73. doi: 10.1016/j.anaerobe.2015.04.012. Epub 2015 Apr 27.
2
An Observational Cohort Study of Ribotype 027 and Recurrent Infection.027 型与再感染的观察性队列研究。
mSphere. 2018 May 23;3(3). doi: 10.1128/mSphere.00033-18. eCollection 2018 May-Jun.
4
Fecal microbiota transplantation for treatment of patients with recurrent infection.粪便微生物群移植治疗复发性感染患者。
Expert Rev Anti Infect Ther. 2020 Jul;18(7):669-676. doi: 10.1080/14787210.2020.1752192. Epub 2020 Apr 12.
8
Microbiologic factors affecting Clostridium difficile recurrence.影响艰难梭菌复发的微生物因素。
Clin Microbiol Infect. 2018 May;24(5):476-482. doi: 10.1016/j.cmi.2017.11.017. Epub 2017 Dec 5.
10
Pediatric Fecal Microbiota Transplantation in Recurrent .儿科粪便微生物群移植治疗复发性.
Pediatr Ann. 2021 Dec;50(12):e515-e521. doi: 10.3928/19382359-20211111-01. Epub 2021 Dec 1.

引用本文的文献

6
Phenylthiazoles with potent & optimum selectivity toward .对……具有强效且最佳选择性的苯并噻唑。
RSC Med Chem. 2024 Mar 22;15(6):1991-2001. doi: 10.1039/d4md00164h. eCollection 2024 Jun 19.
7
Reviewing the Mouse Model: Insights into Infection Mechanisms.回顾小鼠模型:对感染机制的见解。
Microorganisms. 2024 Jan 27;12(2):273. doi: 10.3390/microorganisms12020273.
8
Immunization Strategies Against Clostridioides difficile.针对艰难梭菌的免疫策略。
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.

本文引用的文献

1
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验